Skip to content
UPXI

UPEXI, INC.

UPEXI, INC. Q4 FY2023 earnings call

October 6, 2023 · fiscal period ended 2023-06

EPS · actual vs est

/

Revenue · actual vs est

/
Ask about this call

Summary

Generated 2023-10-06

Management highlights

• Acquired and grew high-growth brands like VitaMetica, Lucky Tail, and Tytan Tiles, with each positioned in high-growth markets. • Leveraged ecosystem driven by data and AI, integrating popular brands and partnerships like Disney. • Executed on business model by optimizing sales performance, expanding margins, and launching complementary products. • Achieved synergies to manage expenses and maximize margins, with plans to continue margin expansion. • Tytan Tiles has a licensing agreement with Disney for branded products to be launched in 2023 holiday season.

View in transcript ↓

Segment performance

In 2023, Upexi's revenue from ecommerce brands and re-commerce was $80.7 million, a 250% increase year-over-year. VitaMetica, acquired in late 2021, has seen 88% organic growth in its product line since acquisition. Lucky Tail, acquired in August 2022, launched new all-natural pet supplements. Tytan Tiles, acquired in October 2022, is available in over 3,900 Walmart stores and has a licensing agreement with Disney. Cygnet Online, acquired in 2022, is now 100% owned. VitaMetica contributed to growth through organic expansion, Lucky Tail via new product launches, Tytan Tiles via retail expansion and Disney licensing, and Cygnet via re-commerce integration.

View in transcript ↓

Guidance

• 2023 revenues were $80.7 million, up 250% y-o-y. • Q1 2024 revenues expected to be the biggest quarter in company history. • Bloomios manufacturing business remains in-house, but impact on Q1 guidance uncertain due to ongoing cleanup of unresolved matters with Bloomios. • Anticipate holiday quarter to be strong due to historical boosts and ongoing initiatives like Disney partnerships and retail expansions.

View in transcript ↓

Risks

• Market conditions including exponential interest rate increases and difficult equity markets for growth companies. • Uncertainties related to ongoing issues with Bloomios affecting operational reporting and revenue recognition. • Risks associated with revenue recognition from discontinued operations, especially with Infusionz and Interactive Offers.

View in transcript ↓

Q&A highlights

Q: Talk about fiscal 4Q revenue being softer but profitability improving.

A: Revenue softness due to market changes like slower product turnover on Amazon; profitability improved through cost-cutting measures like closing California facility.

Q: Discuss Bloomios business and its impact on P&L and Q1 guidance.

A: Manufacturing business remains in-house, but exact impact on Q1 guidance unclear due to ongoing cleanup of unresolved matters with Bloomios; partial revenue from Bloomios expected in current quarter but exact numbers still uncertain.

View in transcript ↓

Key numbers

Reported versus consensus

Earnings calendar feed

MetricReportedConsensusDeltaPrior year
EPS
Revenue

Transcript

October 6, 2023

Full transcript unavailable for redistribution

The structured summary above covers the available call sections. Full transcript text is not included on this page.

Continue exploring

Prior quarters

This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.